ADVERTISEMENT
Aurobindo Pharma Unit Gets 3 Observations From USFDA After Inspection
Aurobindo Pharma's subsidiary, Eugia Steriles, received three observations from the USFDA after an inspection of its manufacturing unit in Andhra Pradesh.
05 Apr 2024, 07:51 PM IST 
Save
A batch of medicine bottles at a Aurobindo Pharma plant. (Source: Company website)
Show Quick Read
Summary is AI Generated. Newsroom Reviewed
Aurobindo Pharma on Friday said the U.S. health regulator has issued three observations after inspecting the Andhra Pradesh-based manufacturing unit of its subsidiary.
The U.S. Food and Drug Administration inspected the new injectable facility of Eugia Steriles, a step-down subsidiary of the company, situated in Anakapalli district of Andhra Pradesh, from March 28 to April 5, 2024, the drug firm said in a regulatory filing.
The inspection closed with three observations, it added.
The observations are procedural in nature and will be responded to within the stipulated time, Aurobindo Pharma said.
Shares of the company on Friday ended 0.02% lower at Rs 1,123.75 apiece on the BSE.
